Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF/UMEC/VI vs FF/VI or UMEC/VI in COPD Exacerbations
CTR20150728Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fluticasone furoate + umeclidinium bromide + vilanterol trifenatate in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Jan 2016; status: completed.
02
Drugs
fluticasone furoate + umeclidinium bromide + vilanterol trifenatate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20150728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150728.